ClinicalTrials.gg
CompletedNCT05737160Updated May 23, 2025

Study of Telitacicept in Generalized Myasthenia Gravis

A Phase 3 interventional study of Telitacicept and Placebo in Myasthenia Gravis, Generalized, sponsored by RemeGen Co., Ltd.. Completed at 51 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Enrollment
18th of 67
114 · median 40
Started
2023
with 6 others
Phase 3
24 of 88
7 open now
Registered
34th of 88
by date
Lead sponsor
3 of 88
RemeGen Co., Ltd.

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 18th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2023, is one of 24 in phase 3, and was the 34th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.

Read the detailed description

This study consists of a screening period, a double-blind treatment period (part A) and an open-label treatment period (part B). After screening, eligible subjects will be randomized in a 1: 1 ratio to receive either subcutaneous Telitacicept 240 mg or placebo once a week for 24 doses (part A). Completing part A, subjects will automatically enter part B. In part B, all subjects will receive weekly subcutaneous Telitacicept 240 mg for 24 weeks.

03

Conditions studied

  • Myasthenia Gravis, Generalized

Keywords

  • Myasthenia Gravis
  • Autoimmune Diseases
  • Muscle Weakness
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written provided;
  2. Male or female patients aged 18-80 years;
  3. Diagnosis with generalized myasthenia gravis;
  4. MGFA Class II, III, or IVa;
  5. AChR-Ab or MuSK-Ab positive;
  6. A total MG-ADL score of ≥ 6 with less than 50% of the total score due to ocular symptoms;
  7. QMG ≥ 8, with ≥ 4 items score at least 2;
  8. Have been on a stable MG SoC regimen.

Exclusion criteria

Exclusion Criteria:

  1. Patients with diseases other than MG;
  2. Abnormal laboratory results;
  3. Use of other than standard therapy within 1 month before randomization;
  4. Use of biologic agents targeting therapy, such as Rituximab or complement C5 inhibitors, within 6 months before randomization;
  5. Use of neonatal Fc receptor (FcRn) antagonists, intravenous immunoglobulin (IVIg), or plasmapheresis within 2 months before randomization;
  6. Significant cardiovascular disease, liver, kidney, respiratory, endocrine or hematologic disease, or other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study or require hospitalization during the study;
  7. Acute or chronic infection requiring treatment;
  8. Current active hepatitis;
  9. antibody positive;
  10. Patients currently suffering from thymoma-associated immunodeficiency syndrome (Good's syndrome) or who underwent thymectomy within 6 months before screening;
  11. Received or plan to receive any within 3 months prior to randomization;
  12. Patients with malignant tumors;
  13. Allergy to biological products of human origin;
  14. Participation in any clinical trial 28 days prior to randomization or within 5 times the half-life of an drug (whichever is longer);
  15. Pregnant or lactating women, and those intending to become pregnant during the trial;
  16. Patients considered unsuitable by the investigator to participate in the trial (e.g., patients with severe mental disorders);

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Telitacicept

    Participants will receive subcutaneous Telitacicept 240 mg once a week for a total of 48 doses in addition to MG SoC.

    Biological: Telitacicept

  • Placebo comparator
    Placebo

    Participants will receive subcutaneous placebo once a week for a total of 24 doses (part A) and then weekly subcutaneous Telitacicept 240 mg for 24 doses (part B) in addition to MG SoC.

    Drug: Placebo

Interventions

  • BiologicalTelitacicept

    Administered as an SC infusion

    Also known as: RC18

  • DrugPlacebo

    Administered as an SC infusion

06

What researchers measure

Primary outcomes

  1. Change from baseline in MG-ADL

    The MG-ADL is an 8-item patient-reported scale that measures MG symptoms and functional status. Each item ranges from 0 to 3 for a total score range of 0 to 24.

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in MG-ADL

    The MG-ADL is an 8-item patient-reported scale that measures MG symptoms and functional status. Each item ranges from 0 to 3 for a total score range of 0 to 24.

    Time frame: Weeks12, 36, 48

  2. Change from baseline in QMG

    The quantitative myasthenia gravis (QMG) score is a 13-item scale used to quantify disease severity in myasthenia gravis (MG). Total QMG score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits).

    Time frame: Weeks 12, 24, 36, 48

  3. Proportion of subjects with ≥ 3 points reduction from baseline in MG-ADL

    The MG-ADL is an 8-item patient-reported scale that measures MG symptoms and functional status. Each item ranges from 0 to 3 for a total score range of 0 to 24.

    Time frame: Weeks 24, 48

  4. Proportion of subjects with a decrease of ≥ 5 points from baseline in QMG

    The quantitative myasthenia gravis (QMG) score is a 13-item scale used to quantify disease severity in myasthenia gravis (MG). Total QMG score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits).

    Time frame: Weeks 24, 48

07

Study locations

51 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
  • Anhui Provincial Hospital
    Hefei, Anhui, China
  • Beijing Hospital
    Beijing, Beijing, China
  • Xuanwu Hospital of Capital Medical University
    Beijing, Beijing, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
  • Nanyang First People's Hospital
    Nanyang, Henan, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)
    Wuhan, Hubei, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Inner Mongolia Autonomous Region People's Hospital
    Huhhot, Inner Mongolia, China
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin, China
  • The First Hospital of Jilin University
    Changchun, Jilin, China
  • Dalian Municipal Central Hospital
    Dalian, Liaoning, China
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning, China
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, Liaoning, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning, China
  • The Second Affiliated Hospital of PLA Air Force Military Medical University
    Xi'an, Shaanxi, China
  • Xi'an Hi-tech Hospital
    Xi'an, Shaanxi, China
  • Xianyang Hospital of Yan'an University
    Xianyang, Shaanxi, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Jining No.1 People's Hospital
    Jining, Shandong, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan, China
  • First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Sir Run Run Shaw Hospital, affiliated with to Zhejiang University College of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2024, 19 months.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2023
First posted
Feb 21, 2023
StartActual
Mar 28, 2023
Primary completionActual
Nov 26, 2024
CompletionActual
Dec 12, 2024
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05737160
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Mar 28, 2023
Primary completion
Nov 26, 2024
Completion
Dec 12, 2024
Last update
May 23, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion